December 2017

New Product - Kisqali

Kisqali (ribociclib (succinate)) selectively inhibits cyclin dependent kinase (CDK) 4 and 6. These kinases are activated upon binding to D-cyclins and play a crucial role in signalling pathways which lead to cell cycle progression and cellular proliferation. Kisqali in combination with an aromatase inhibitor is indicated for the treatment of men and postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer, as an initial endocrine based therapy. Kisqali is contraindicated with corrected QT interval (QTcF) > 450 milliseconds prior to treatment or in patients who already have long QT syndrome or who are at significant risk of developing QTc prolongation. Kisqali tablets (ribociclib 200 mg) are available in packs of 21, 42 and 63.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au